National Institute of Diabetes and Digestive and Kidney Disorders; Notice of Closed Meeting, 6025 [05-2131]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 23 / Friday, February 4, 2005 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Notice of Meeting: Secretary’s
Advisory Committee on Genetics,
Health, and Society
Pursuant to Public Law 92–463,
notice is hereby given of the sixth
meeting of the Secretary’s Advisory
Committee on Genetics, Health, and
Society (SACGHS), U.S. Public Health
Service. The meeting will be held from
8:30 a.m. to 5:30 p.m. on February 28,
2005 and 8:30 a.m. to 5 p.m. on March
1, 2005 at the Bethesda North Marriott
Hotel, 5701 Marinelli Road, North
Bethesda, Maryland. The meeting will
be open to the public with attendance
limited to space available. The meeting
will be webcast.
The meeting is expected to include
presentations and deliberations on
several topics, including the following:
a revised draft report with
recommendations about coverage and
reimbursement for genetic technologies
and services; current and proposed
efforts to understand gene-environment
interactions through large population
studies; the Committee’s efforts to
explore stakeholder perspectives on the
need for Federal legislation to prevent
genetic discrimination in health
insurance and employment; the
recommendations of the Advisory
Committee on Heritable Disorders and
Genetic Diseases in Newborns and
Children regarding the provision of
screening, counseling and health care
services for newborns and children
having or at risk for heritable disorders;
and efforts to improve the quality of
laboratory testing for rare diseases. Time
will be provided each day for public
comments.
Under authority of 42 U.S.C. 217a,
Section 222 of the Public Health Service
Act, as amended, the Department of
Health and Human Services established
SACGHS to serve as a public forum for
deliberations on the broad range of
human health and societal issues raised
by the development and use of genetic
technologies and, as warranted, to
provide advice on these issues. The
draft meting agenda and other
information about SACGHS, including
information about access to the webcast,
will be available at the following Web
site: https://www.od.nih.gov/oba/
sacghs.htm.
The Committee would welcome
hearing from anyone wishing to provide
public comment on any issue related to
genetics, health and society. Individuals
who would like to provide public
VerDate jul<14>2003
18:52 Feb 03, 2005
Jkt 205001
comment or who plan to attend the
meeting and need special assistance,
such as sign language interpretation or
other reasonable accommodations,
should notify the SACGHS Executive
Secretary, Ms. Sarah Carr, by telephone
at 301–496–9838 or e-mail at
sc112@nih.gov. The SACGHS office is
located at 6705 Rockledge Drive, Suite
750, Bethesda, MD 20892.
Dated: January 27, 2005.
LaVerne Stringfield,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–2128 Filed 2–3–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
6025
Contact Person: Dr. Myrlene Staten, Senior
Advisor, Diabetes Translation Research,
Division of Diabetes, Endocrinology and
Metabolic Diseases, NIDDK, NIH, 6707
Democracy Boulevard, Bethesda, MD 20892–
5460. (301) 402–7886.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research,
93.848, Digestive Diseases and Nutrition
Research; 98.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS.)
Dated: January 26, 2005
LaVerne Y. Stringfield,
Director, Office of Federal Advisory
Committee Policy.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
[FR Doc. 05–2131 Filed 2–3–05; 8:45 am]
National Institutes of Health
BILLING CODE 4140–01–M
National Institute of Diabetes and
Digestive and Kidney Disorders;
Notice of Closed Meeting
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2) notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The purpose of this
meeting is to evaluate requests for
preclinical development resources for
potential new therapeutics for type 1
diabetes. The outcome of the evaluation
will be a decision whether NIDDK
should support the request and make
available contract resources for
development of the potential
therapeutic to improve the treatment or
prevent the development of type 1
diabetes and its complications. The
reserach proposals and the discussions
could disclose confidential trade secrets
or commercial property such as
patentable material, and personal
information concerning individuals
associated with the proposed research
projects, the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Type 1 Diabetes—
Rapid Access to Intervention Development
Special Emphasis Panel, National Institute of
Diabetes and Digestive and Kidney Diseases.
Date: February 9, 2005.
Time: 10 a.m.–2 p.m.
Agenda: To evaluate requests for
preclinical development resources for
potential new therapeutics for type 1 diabetes
and its complications.
Place: 6707 Democracy Boulevard,
Bethesda, MD 20892. (Telephone conference
call.)
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
National Institutes of Health
National Library of Medicine; Notice of
Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the third meeting of
the Commission on Systemic
Interoperability.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The mission of the Commission on
Systemic Interoperability is to submit a
report to the Secretary of Health and
Human Services and to Congress on a
comprehensive strategy for the adoption
and implementation of health care
information technology standards that
includes a timeline and prioritization
for such adoption and implementation.
In developing that strategy, the
Commission will consider: (1) The costs
and benefits of the standards, both
financial impact and quality
improvement; (2) the current demand
on industry resources to implement the
Medicare Prescription Drug,
Improvement, and Modernization Act of
2003 and other electronic standards,
including HIPAA standards; and (3) the
most cost-effective and efficient means
for industry to implement the standards.
Name of Committee: Commission on
Systemic Interoperability.
E:\FR\FM\04FEN1.SGM
04FEN1
]]>Agencies
[Federal Register Volume 70, Number 23 (Friday, February 4, 2005)]
[Notices]
[Page 6025]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-2131]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney
Disorders; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2) notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The purpose of this meeting is to evaluate requests
for preclinical development resources for potential new therapeutics
for type 1 diabetes. The outcome of the evaluation will be a decision
whether NIDDK should support the request and make available contract
resources for development of the potential therapeutic to improve the
treatment or prevent the development of type 1 diabetes and its
complications. The reserach proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the proposed research projects, the disclosure of which
would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Type 1 Diabetes--Rapid Access to Intervention
Development Special Emphasis Panel, National Institute of Diabetes
and Digestive and Kidney Diseases.
Date: February 9, 2005.
Time: 10 a.m.-2 p.m.
Agenda: To evaluate requests for preclinical development
resources for potential new therapeutics for type 1 diabetes and its
complications.
Place: 6707 Democracy Boulevard, Bethesda, MD 20892. (Telephone
conference call.)
Contact Person: Dr. Myrlene Staten, Senior Advisor, Diabetes
Translation Research, Division of Diabetes, Endocrinology and
Metabolic Diseases, NIDDK, NIH, 6707 Democracy Boulevard, Bethesda,
MD 20892-5460. (301) 402-7886.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research, 93.848, Digestive
Diseases and Nutrition Research; 98.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS.)
Dated: January 26, 2005
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
[FR Doc. 05-2131 Filed 2-3-05; 8:45 am]
BILLING CODE 4140-01-M
